Florida Society of Clinical Oncology MEC 20th Annual Miami Cancer Meeting 2024

Description Include: 26 videos 1 pdf, size: 3.31 GB Target Audience: medical oncologists, hematologists, radiation oncologists, surgical oncologists, physician associates Sample video: contact me for sample video Information: Start: 19 January 2024 End: 21 January 2024 Venue: The Westin Tampa Waterside Hotel Conference Description The areas of focus for this conference will include the current standards of care in the treatment of the aforementioned malignancies and new developments in theSe areas of Cancer care. There Will be much emphasis on molecular diagnosis and individualization of cancer therapy based on molecular profiles. There will be reviews of new chemOtherapeutic, antiangiogenic, and immUnotherapeutic agents. Topics in solid tumors and hematological malignancies will be reviewed and will include tepics in breast cancer, lung cancer, gastrointestinal (GI) malignancies, gynecologic malignancies, genitourinary (GU) cancers head and neck cancers, melanoma, and hematological malignancies such as multiple myeloma, CLL and non-Hodgkin’s-lymphoma. There will also be a special session devoted to toxicity profiles, sUpportive care, and challenges in cancer therapy. Presentations from the latest national (AACR, ASCO, SABC, and ASH) and international forums (ESMO and WCLC) meetings Will be discussed and guidelines of cancer care using a team approach will be emphasized. The participants in the conference will have the opportunity not only to learn, review,- and understand the state-of-the-art‘ management in cancer care using a team approach but also engage in personal interaction with our panel of exports in these subjects during the questions and answers sessions. This 3-day conference is designed for medical oncologists, hematologists, radiation oncologists, surgical oncologists, physician associates (PA), advanced registered nurse practitioners (ARNP), oncology nurses, registered pharmacists, pharmacy technicians, and radiation therapists. General practitioners will have the benefit of reviewing standard care and new developments in cancer management. Residents in training and fellows from these, specialties are encouraged to attend.   Topics: Acute Myeloid Leukemia.mp4 B-Cell NHL (Aggressive) – Relapsed (CAR T versus Bispecifics).mp4 B-Cell NHL (Low-Grades).mp4 Bi-Specific Inhibitor & ADC in Lung Cancer.mp4 Challenges in Targeting Head and Neck Squamous Cell Carcinoma.mp4 Chronic Lymphocytic Leukemia.mp4 Controversies in Breast Cancer Use of ctDNA to Tailor Systemic Adjuvant & Post-neoadjuvant Therapies (Part 1).mp4 Controversies in Breast Cancer Use of ctDNA to Tailor Systemic Adjuvant & Post-neoadjuvant Therapies (Part 2).mp4 Controversies in Lung Cancer Neoadjuvant vs Adjuvant IO in Early Stage NSCLC.mp4 Endocrine Therapy for Early -and Late- Stages Breast Cancer Therapeutic Updates.mp4 Flyer.pdf Front Line Targeted Therapy in NSCLC Tyrosine Kinase Inhibitors.mp4 HER-2 Disease Amplification, Overexpression, Mutation in Breast Cancer.mp4 How to Handle Myelotoxicity from Chemotherapy in 2024 From Colony-Stimulating Factors (CSF) to Agents Providing Myeloprotection.mp4 Immunotherapy in Breast Cancer Now & The Future.mp4 Immunotherapy in NSCLC First Line for Advanced Disease.mp4 Kidney & Bladder Cancer Targeted, Immuno & Other Strategies.mp4 Management of Malignant Hypercalcemia, Bone Metastases & Standard Precautions to Decrease Adverse Events.mp4 Myelodysplasia De Novo and Acquired- What To Do.mp4 New Platforms and Developments of Immunotherapy Biomarkers Beyond PD-L1 in Tissue.mp4 Novel Advances in Multiple Myeloma as Front-Line Therapy.mp4 Prostate Cancer Diagnostic and Therapeutic Updates.mp4 Small Cell Lung Cancer.mp4 Targeted Therapy and Immunotherapy for Soft Tissue Tissue Sarcomas.mp4 Triple Negative Breast Cancer Optimal Strategies.mp4 Updates in Waldenstroms Macroglobulinemia.mp4 What To Do When Patients Getting Immunotherapy Do Not Respond to Steroids (Hepatitis, Colitis, Pneumonitis, and Others).mp4